Lunai Bioworks (LNAI) Research & Development (2015 - 2026)
Lunai Bioworks (LNAI) posted quarterly Research & Development of $15946.0 for Q1 2026, up 116.95% year-over-year from $7350.1 in Q1 2025, and down 65.24% quarter-over-quarter from $45872.0 in Q4 2025.
Lunai Bioworks (LNAI) Research & Development (2015 - 2026) Analysis & Trends
Lunai Bioworks' Research & Development history runs 12 years deep, the most recent figure standing at $15946.0 for Q1 2026.
- In Q1 2026, Research & Development rose 116.95% year-over-year to $15946.0; the TTM figure through Mar 2026 stood at $166453.0 (down 81.33% YoY), while the FY2025 annual figure was $537428.0, down 80.16% from the prior year.
- Research & Development for Q1 2026 stood at $15946.0, down from $45872.0 in the prior quarter.
- The five-year high for Research & Development was $2.6 million in Q3 2022, with the low at -$94073.0 in Q1 2025.
- The 5-year median for Research & Development is $390189.0 (2024), against an average of $616342.4.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 354.62% in 2024, then tumbled 108.65% in 2025.
- Lunai Bioworks' Research & Development stood at $325959.0 in 2022, then jumped by 90.37% to $620521.0 in 2023, then plunged by 74.04% to $161084.0 in 2024, then sank by 71.52% to $45872.0 in 2025, then tumbled by 65.24% to $15946.0 in 2026.
- Business Quant data shows LNAI's Research & Development at $15946.0 in Q1 2026, $45872.0 in Q4 2025, and $24407.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 15,946.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,946.00 |
| Dec 31, 2025 | 45,872.00 |
| Sep 30, 2025 | 24,407.00 |
| Jun 30, 2025 | 80,228.00 |
| Mar 31, 2025 | -94,073.00 |
| Dec 31, 2024 | 161,084.00 |
| Sep 30, 2024 | 390,189.00 |
| Jun 30, 2024 | 434,508.00 |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 620,521.00 |
| Sep 30, 2023 | 566,644.00 |
| Jun 30, 2023 | 994,726.00 |
| Mar 31, 2023 | 239,137.00 |
| Dec 31, 2022 | 325,959.00 |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 2.34 Mn |
| Sep 30, 2021 | 3.06 Mn |
| Jun 30, 2021 | 12.15 Mn |